If you or a loved one is taking Tysabri, the FDA's warning about progressive multifocal leukoencephalopathy (PML) can be alarming. This page breaks down what the warning actually means, who is at risk, and how clinicians monitor for early signs. Building on decades of pharmacovigilance research, we provide a clear checklist to help you discuss PML risk with your healthcare provider.
Building on the need for targeted risk awareness, we now examine Tysabri (natalizumab), a biologic therapy approved for multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC polyomavirus. The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, due to this risk. The boxed warning states that Tysabri increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Identified risk factors for developing PML include the presence of anti-JCV antibodies, longer duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors must be weighed against expected benefits when initiating or continuing treatment.
PML is a demyelinating disease that progressively damages the brain's white matter. Clinical presentation often includes cognitive decline, motor deficits, visual disturbances, and speech difficulties. Diagnosis relies on neuroimaging, typically magnetic resonance imaging (MRI), and detection of JCV DNA in cerebrospinal fluid. In a large retrospective Italian cohort of 456 PML patients observed between 1987 and 2024, 82.4% had a definite diagnosis, and 17.6% had a clinico-radiological diagnosis (https://pubmed.ncbi.nlm.nih.gov/40922664/). This study highlights the severe nature of PML across various underlying conditions.
The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs immune surveillance against JCV. In immunocompromised individuals, JCV can reactivate and infect oligodendrocytes, leading to demyelination and PML. Clinical trial data documented PML in three patients who received Tysabri. Two cases occurred among 1,869 multiple sclerosis patients treated for a median of 120 weeks, both of whom also received interferon beta-1a. The third case occurred after eight doses in one of 1,043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) has identified thousands of adverse events associated with Tysabri, including fatigue, multiple sclerosis relapse, headache, and gait disturbance (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While PML is not the most frequently reported event, its severity makes it a critical safety concern.
The adequacy of warnings regarding Tysabri and PML is a central issue. The boxed warning explicitly states that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and that Tysabri dosing should be withheld immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, designed to ensure informed prescribing and monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether patients and providers fully understand the risk, especially given the latency between exposure and PML onset. The timeline between Tysabri exposure and documented PML harm varies. In clinical trials, one case occurred after eight doses, while others emerged after longer treatment durations. The risk increases with cumulative exposure, particularly beyond two years of therapy. Patients with prior immunosuppressant use or positive anti-JCV antibody status face higher risk. Early detection through MRI and clinical monitoring is crucial, as PML often leads to irreversible neurological damage or death. For affected patients and their families, attorney-related considerations may include evaluating whether the manufacturer provided adequate warnings about PML risk. The boxed warning and TOUCH program represent regulatory efforts to mitigate harm, but legal claims might focus on whether these measures were sufficient or whether patients were properly informed. Washington residents seeking legal representation for Tysabri-related PML should consult with an attorney experienced in pharmaceutical injury cases. Such attorneys can assess individual circumstances, including the timing of symptoms relative to treatment, the presence of risk factors, and the adequacy of medical monitoring.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning due to this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Risk factors include the presence of anti-JCV antibodies, longer duration of therapy (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Diagnosis involves MRI neuroimaging and detection of JCV DNA in cerebrospinal fluid. Clinical symptoms include cognitive decline, motor deficits, and visual disturbances (https://pubmed.ncbi.nlm.nih.gov/40922664/).
Washington residents may consult an attorney experienced in pharmaceutical injury cases to evaluate whether the manufacturer provided adequate warnings. Legal claims may focus on informed consent and the sufficiency of risk communication.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.